Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Crossover Experiments01:16

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Censoring Survival Data01:09

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different reasons...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of conventional antimicrobial agents against carbapenem resistant non-carbapenem β-lactams susceptible Pseudomonas aeruginosa infection in critically ill patients: a multicentre retrospective study.

BMC infectious diseases·2026
Same author

Therapeutic effects of tDCS on behavioral symptoms of autism spectrum disorders in children and adolescents: A systematic review and meta-analysis of randomized sham-controlled trials.

Brain & development·2026
Same author

Immune Microenvironment and Genetic Signatures of End-Stage Renal Disease and Their Association with Sepsis: Insights from Public Transcriptomic Data and a Multicenter Clinical Cohort.

Biomedicines·2026
Same author

Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens.

Annals of intensive care·2025
Same author

Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.

BMC infectious diseases·2025
Same author

The therapeutic effects of probiotics on core and associated behavioral symptoms of autism spectrum disorders: a systematic review and meta-analysis.

Child and adolescent psychiatry and mental health·2024

Related Experiment Video

Updated: May 26, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Curtailed two-stage designs with two dependent binary endpoints.

Chia-Min Chen1, Yunchan Chi

  • 1National Cheng-Kung University, Department of Statistics, No.1 University Road, Tainan, Taiwan.

Pharmaceutical Statistics
|December 14, 2011
PubMed
Summary

This study enhances two-stage clinical trial designs for cancer drugs by incorporating toxicity and clinical activity endpoints. Applying a curtailed sampling procedure aims to reduce sample sizes and accelerate drug development.

More Related Videos

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

RBDT: A Computerized Task System based in Transposition for the Continuous Analysis of Relational Behavior Dynamics in Humans
11:09

RBDT: A Computerized Task System based in Transposition for the Continuous Analysis of Relational Behavior Dynamics in Humans

Published on: July 17, 2021

Related Experiment Videos

Last Updated: May 26, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

RBDT: A Computerized Task System based in Transposition for the Continuous Analysis of Relational Behavior Dynamics in Humans
11:09

RBDT: A Computerized Task System based in Transposition for the Continuous Analysis of Relational Behavior Dynamics in Humans

Published on: July 17, 2021

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Phase I trials often fail to accurately estimate toxicity frequency.
  • Simultaneous evaluation of clinical activity and safety is crucial for toxic cancer chemotherapies in Phase II trials.
  • Existing multi-stage designs with dependent binary endpoints face challenges in controlling Type I error rates and maintaining power due to typical Phase II sample sizes.

Purpose of the Study:

  • To adapt two-stage clinical trial designs for Phase II trials by integrating toxicity and clinical activity endpoints.
  • To address the limitations of existing designs in controlling Type I error and power with standard sample sizes.
  • To improve the efficiency of drug development by reducing sample sizes and speeding up the process.

Main Methods:

  • The study applies the curtailed sampling procedure, as summarized by Phatak and Bhatt.
  • The methodology focuses on two-stage designs with two dependent binary endpoints.
  • The approach is designed to manage both toxicity and efficacy in early-phase cancer drug trials.

Main Results:

  • The proposed method aims to effectively control the Type I error rate across the null region.
  • The application of curtailed sampling is expected to maintain sufficient statistical power against relevant alternatives.
  • Reduced sample sizes are anticipated, leading to a more efficient trial process.

Conclusions:

  • The integration of curtailed sampling into two-stage designs offers a viable solution for Phase II clinical trials.
  • This approach enhances the ability to simultaneously assess drug efficacy and safety while optimizing resource utilization.
  • The findings suggest a pathway to accelerate the development of new cancer therapeutics.